Biological therapies in Crohn's disease: Are they cost-effective? A critical appraisal of model-based analyses

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 6, 2014, Pages 815-824

  Marchetti, Monia ^a   Liberato, Nicola Lucio ^b  

^a Ospedale Cardinal Massaia   (Italy)

^b Department of Medicine Azienda Ospedaliera Della Provincia di Pavia Ospedale Carlo Mira   (Italy)

Author keywords

Cost effectiveness analysis; Crohn's disease; Decision analysis; Health economics; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; ALPHA4 INTEGRIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; PATIENT SAFETY; QUALITY ADJUSTED LIFE YEAR; REVIEW; ANTAGONISTS AND INHIBITORS; COST CONTROL; DRUG EFFECTS; ECONOMICS; IMMUNOLOGY; MONTE CARLO METHOD; PROBABILITY; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; COST SAVINGS; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG COSTS; GASTROINTESTINAL AGENTS; HUMANS; INTEGRIN ALPHA4; MARKOV CHAINS; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84909981446     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.957682     Document Type: Review

References (57)

1. Hutfless S, Lau BD, Wilson LM, et al. Pharmacological management of crohn's disease: future research needs: identification of future research needs from comparative effectiveness review no. 131. Agency for Healthcare Research and Quality US. 2014; Report No.: 13(14)-EHC017-EF
2. Terdiman JP, Gruss CB, Heidelbaugh JJ, AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013;145(6):1459-63
3. Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011;43(1):1-20
4. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Chrohn's Colitis 2010;4(1):28-62
5. Kawalec P, Mikrut A, Wis̈niewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci 2013;9(5):765-79
6. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013;145(6):1464-78
7. Zhang D, Xiong B, Li X, et al. Metaanalysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors. Hepatogastroenterology 2013;60(126):1333-42
8. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013;108(8):1268-76
9. Sandborn WJ, Colombel JF, Enns R, et al. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25
10. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357(3):228-38
11. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369(8):711-21
12. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24(2):319-28
13. Di Sabatino A, Liberato L, Marchetti M, et al. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med 2011;6(suppl 1):S17-27
14. Odes S, Vardi H, Friger M, et al. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis. Aliment Pharmacol Ther 2010;31(7):735-44
15. Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α)inhibitors, adalimumab and infliximab for Crohn's disease. Health Technol Assess 2011;15(6):1-250
16. Tang DH, Harrington AR, Lee JK, et al. A systematic review of economic studies on biological agents used to treat Crohn's disease. Inflamm Bowel Dis 2013;19(12):2673-94
17. de Pouvourville G1, Ulmann P, Nixon J, et al. The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project. Pharmacoeconomics 2005;23(2):113-20
18. Husereau D, Drummond M, Petrou S, et al. CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care 2013;29(2):117-22
19. Gaultney JG, Redekop WK, Sonneveld P, Uyl-de Groot CA. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Eur J Cancer 2011;47(10):1458-67
20. Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR. Strategies for the prevention of postoperative recurrences in Crohn's disease: results of a decision analysis. Am J Gastroenterol 2011;106(11):2009-17
21. Punekar YS, Sunderland T, Hawkins N, Lindsay J. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. Value Health 2010;13(2):188-95
22. Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28(1):76-87
23. Arsenau KO, Cohn SM, Cominelli F, Connors AF. Cost-utility of initial medical management of Crohn's disease perianal fistulae. Gastroenterology 2001;120(7):1640-56
24. Jaisson-Hot I, Flouriè B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004;20(3):274-9
25. Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ 2013;14(6):853-61
26. Marshall J, Blackhouse G, Goeree R, et al. Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis. Technology report n. 24. Canadian Coordinating Office for Health Technology Assessment, Ottawa; 2002. Available from: www.cadth.ca/media/pdf/122-infliximab-tr-e.pdf [Last accessed 21 June 2014]
27. Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Di Dis Sci 2012;57(2):472-80
28. Tang DH, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn' disease. Pharmacotherapy 2012;32(6):515-26
29. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26(11-12):1509-20
30. Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. J Crohn's Colitis 2012;6(1):77-85
31. Saito S, Shimizu U, Nan Z, et al. A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn's disease. Health 2014.6(1):107-14. Available from: http://dx.doi.org/10.4236/health.2014.61017 [Last accessed 21 June 2014]
32. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
33. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2(10):912-20
34. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33
35. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56(9):1232-39
36. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146(12):829-38
37. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007;132(5):1672-83
38. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371(9613):660-7
39. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95
40. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117(1):49-57
41. Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997;3(4):265-76
42. Casellas S, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005;11(5):488-96
43. Saito S, Shimizu U, Nan Z, et al. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis. J Crohn's Colitis 2013;7(2):167-74
44. Malone DC, Waters HC, Van Den Bos J, et al. A claims-based Markov model for Crohn's disease. Aliment Pharmacol Ther 2010;32(3):550-5
45. Yu AP, Johnson S, Wang AT, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics 2009;27(7):609-21
46. Loftus EV Jr, Johnson SJ, Yu AP, et al. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol 2009;21(11):1302-9
47. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009;30(3):265-74
48. Waljee AK, Morris AM, Waljee JF, et al. Individual health discount rate in patients with ulcerative colitis. Inflamm Bowel Dis 2011;17(6):1328-32
49. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24(2):319-28
50. Binion DG, Louis E, Oldenburg E, et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Can J Gastroenterol 2011;25(9):492-6
51. Casellas F, Barreiro de Acosta M, Iglesias M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012;24(7):762-9
52. Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005;21(11):1741-54
53. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138(2):463-8
54. Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 2013; doi; 10.1016/j.cgh.2013.09.006. [Epub ahead of print]
55. Bouguen G, Levesque BG, Pola S, et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12(6):978-85
56. Nord E, Johansen R. Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY. Health Policy 2014;116(2-3):281-8
57. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003;7(3):1-77